Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer—Reply
Author:
Affiliation:
1. University of California, San Francisco
2. University of Texas MD Anderson Cancer Center, Houston
Publisher
American Medical Association (AMA)
Subject
Oncology,Cancer Research
Link
https://jamanetwork.com/journals/jamaoncology/articlepdf/2789389/jamaoncology_mukhtar_2022_lr_210040_1662060003.67346.pdf
Reference5 articles.
1. Assessment of residual cancer burden and event-free survival in neoadjuvant treatment for high-risk breast cancer: an analysis of data from the I-SPY2 randomized clinical trial.;Symmans;JAMA Oncol,2021
2. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.;Early Breast Cancer Trialists’ Collaborative Group (EBCTCG);Lancet Oncol,2018
3. Abstract P2-14-01: the impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 trial.;Silverstein;Cancer Res,2019
4. Abstract CT003: analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 trial.;Campbell;Cancer Res,2019
5. Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 trial.;Li;NPJ Breast Cancer,2020
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2023 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3